FY2024 Earnings Forecast for KYTX Issued By Leerink Partnrs

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Kyverna Therapeutics in a report released on Wednesday, November 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($3.33) per share for the year, up from their previous estimate of ($3.54). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.31) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($4.35) EPS, FY2026 earnings at ($4.73) EPS, FY2027 earnings at ($5.68) EPS and FY2028 earnings at ($6.03) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter.

Several other equities analysts have also commented on KYTX. HC Wainwright reaffirmed a “neutral” rating and set a $7.00 target price on shares of Kyverna Therapeutics in a report on Thursday, September 19th. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. UBS Group initiated coverage on Kyverna Therapeutics in a research report on Thursday, October 10th. They issued a “buy” rating and a $13.00 target price on the stock. Wells Fargo & Company reduced their price target on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a report on Friday. Finally, Rodman & Renshaw started coverage on shares of Kyverna Therapeutics in a research report on Wednesday, October 9th. They set a “buy” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.86.

Kyverna Therapeutics Stock Up 1.3 %

Shares of NASDAQ:KYTX opened at $4.41 on Monday. Kyverna Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $35.06. The firm has a 50-day simple moving average of $5.46 and a 200 day simple moving average of $8.42.

Institutional Trading of Kyverna Therapeutics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in Kyverna Therapeutics by 19.0% in the third quarter. Geode Capital Management LLC now owns 443,312 shares of the company’s stock worth $2,168,000 after purchasing an additional 70,714 shares during the period. Barclays PLC lifted its holdings in shares of Kyverna Therapeutics by 21.5% in the third quarter. Barclays PLC now owns 70,167 shares of the company’s stock valued at $343,000 after buying an additional 12,418 shares during the period. Jane Street Group LLC boosted its stake in Kyverna Therapeutics by 78.3% during the third quarter. Jane Street Group LLC now owns 39,193 shares of the company’s stock valued at $192,000 after buying an additional 17,215 shares in the last quarter. Sphera Funds Management LTD. grew its holdings in Kyverna Therapeutics by 5.3% during the third quarter. Sphera Funds Management LTD. now owns 248,651 shares of the company’s stock worth $1,216,000 after acquiring an additional 12,622 shares during the period. Finally, State Street Corp raised its position in Kyverna Therapeutics by 3.2% in the third quarter. State Street Corp now owns 326,192 shares of the company’s stock worth $1,595,000 after acquiring an additional 10,244 shares in the last quarter. 18.08% of the stock is owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.